T he co-occurrence of medical illness among persons with schizophrenia has been addressed in epidemiological prevalence studies, studies reporting early or increased mor-tality, studies reporting an increased risk for HIV, studies outlining barriers to health care delivery, and most recently with regard to the association with the development of diabetes mellitus. 1-11 Persons with schizophrenia may have fewer medical visits, fewer documented medical problems, and be less likely to receive a detailed physical examination. 7 Dixon et al. 12 reported that subjects in the Schizophrenia Patient Outcomes Research Team (PORT) most commonly self-reported problems with eyesight, teeth, and high blood pressure. Among persons in that sample, current medical problems independently contributed to more severe psychosis and depression. 12 The 12-month prevalence of 8 medical disorders among Medicaid beneficiaries with psychotic disorders and substance abuse disorders was significantly elevated compared with beneficiaries without these psychiatric disorders. Most recently, Sokal et al. 11 reported that persons with schizophrenia had greater odds of respiratory illnesses, even when controlling for smoking. Medical illnesses among persons with schizophrenia also tend to be more severe. 11, 12 These studies support earlier literature that a significant medical burden exists for persons with schizophrenia. The results are compelling, but the significance of the findings may be restricted because of limitations in study design including (1) small nonrepresentative samples, (2) patient self-report of medical conditions, (3) cross-sectional chart reviews, and (4) poorly defined criteria for chronic medical conditions. Therefore, we conducted a population-based study, spanning multiple years, and using criteria validated for the detection of chronic medical conditions for administrative claims data. Research of this type lays the framework for refining strategies for the prevention, screening, and treatment of seriously mentally ill patients in primary care settings.
METHODS

Data Source
We conducted a population-based controlled study using a 100% sample of Wellmark Blue Cross/Blue Shield of Iowa administrative claims data from January 1, 1996 to December 31, 2001 . These data are composed of inpatient and outpatient claims submitted by all health care providers and includes International Classification of Diseases (ICD-9) JGIM diagnostic codes and Current Procedural Terminology Codes {CPT).
Population
The eligible study population included all subjects ages 18 to 64 who filed at least 1 claim for medical service during the study period, 1996 to 2001. All subjects were residents of Iowa and were classified as residing in a rural or urban county based on the metropolitan statistical area definition. 13 The basic medical insurance coverage was similar among subjects, with only a small proportion (< 10%) enrolled in a managed care plan.
The case population was composed of subjects diagnosed with schizophrenia (ICD-9 295.0 to 295.3, 295.5 to 295.6, 295.8 to 295.9) or schizoaffective disorder (ICD-9 295.7) in the inpatient or outpatient setting during 1996 to 2001. These diagnoses will be described as schizophrenia throughout the remainder of the text. Subjects were included provided that schizophrenia was the most clinically predominant disorder, regardless of whether other mental disorders (e.g., depression) were also present. The most clinically predominant disorder was determined by the number of claims for schizophrenia based on the following criteria: (1) number of hospitalizations for the given condition, and then (2) number of psychiatrist visits for the condition, then (3) number of any other outpatient claims for the condition. Subjects with claims for both schizophrenia and bipolar disorder were included if schizophrenia was more predominant than bipolar disorder.
The control population consisted of men and women who had no mental disorder claims during 1996 to 2001.
Comorbidity
The Elixhauser Comorbidity Index was used to assess medical 1 ~, comorbidity using inpatient and outpatient claims data. The Elixhauser index was first used to describe chronic medical conditions most commonly occurring in hospitalized persons. As modified and validated by Klabunde, comorbid outpatient conditions were also counted if the condition occurred either in the inpatient setting or in 2 or more outpatient claims coded in a period of no fewer than 30 days during 1996 to 2001.15 This time period was used to ensure that acute or miscoded outpatient comorbidities were not included in the total comorbidity count. Twenty six comorbidities were selected from the Elixhauser Comorbidity index based on prevalence in the general population and prior research on medical co-morbidity in schizophrenia, Using the same methodology, we also examined twelve additional medical co-morbidities prevalent in the adult population (stroke, ischemic heart disease, hyperlipidemia, pancreatitis, hepatitis C, other viral hepatitis, backache, arthritis, asthma, accidents/injuries, benign prostatic hyperplasia, and headache), and 5 specific comorbidities unique to women's health care (cystitis, mammary dysplasia, endometriosis, inflammatory disease of the ovary, and disorders of menstruation). Finally, we included nicotine, polysubstance, and alcohol abuse/dependence conditions as comorbidities, given the likelihood of these conditions to complicate the course of underlying medical illness.
Statistical Analyses
Demographic and clinical characteristics were analyzed using X 2 tests for categorical variables and t tests for continuous variables. Demographic variables included gender, age. urban or rural residence, number of months eligible for medical care as calculated from the first medical claim date to the last medical claim date, and number of nonmental health care visits. Membership files with actual dates of enrollment in Blue Cross/Blue Shield were unavailable. Comorbidity was further categorized as the presence of 0, 1, 2, 3+ total conditions described above.
Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CI) for each of the 46 comorbidities examined. Odd ratios were adjusted for gender, age, residence (rural vs urban), and nonmental health care utilization. Odd ratio for comorbidities specific to 1 gender (e.g., benign prostatic hyperplasis, cystitis) were not adjusted for gender. We adjusted for utilization by controlling for the number of known nonmental health encounters in order to take into account potential differences in diagnostic patterns attributed to contact with a provider during the time of observation from the first to the last known claim. All statistical tests were 2 sided, with an a of 0.05. All analyses were performed with SAS version 8.2.16 Only adjusted findings are reported.
The Institutional Review Boards at Indiana University and the University of Iowa approved this study.
RESULTS
Overall, 569 (53%) women and 505 {47%) men were identified with schizophrenia. The mean age of the cases was 40.2 years (SD, 11.9 years). Persons with schizophrenia had significantly more months of follow-up, more overall health care visits, and were only slightly more likely to live in urban settings than controls, persons without schizophrenia (Table 1) . Over 33% of cases had 3 or more medical comorbidities, nearly 3 times more than controls (33.2% vs 12.1%, respectively).
In the adjusted analyses, persons with schizophrenia had increased ORs for conditions spanning nearly every organ system, and markedly higher ORs for substance abuse and dependence including alcohol 12 15.99 ). However, these findings must be taken in the context of the elevated odds of polysubstance and alcohol abuse. Finally, renal failure (OR 2.94%, 95% CI 1.55 to 5.57) and fluid and electrolyte disorders (OR 4.21%, 95% CI 3.25 to 5.44) also occurred at increased odds. Notable conditions not occurring at increased odds in persons with schizophrenia included hypertension, ischemic heart disease, hyperlipidemia, other hepatitis, and malignancies.
DISCUSSION
Our results are consistent with those from prior studies: persons with schizophrenia have significant increased medical comorbidity for conditions related to modifiable behaviors (e.g., chronic obstructive pulmonary disease), as well as con-]GIM ditions that may influence the course of mental symptoms (e.g., hypothyroidism). We add to prior studies by identifying increased risk for conditions not previously reported, such as deficiency anemias, hypothyroidism, neurological disorders, and fluid and electrolyte conditions. It is possible that such conditions were diagnosed in this insured population because subjects had greater financial access to physician and diagnostic services than the uninsured or underinsured who have previously been studied. It is also noteworthy that the ORs for ischemic heart disease and hypertension were not elevated, given the increased odds for nicotine abuse. We speculate that this is likely because of underdiagnosis of these conditions in this population.
Finally, compared with controls without mental illness, persons with schizophrenia were more likely to have a greater number of conditions spanning several disease categories including cardiovascular, pulmonary, neurological, and endocrine diseases. One-third of this young population (average age 40 years) had 3 or more chronic comorbidities, and only 29% of persons with schizophrenia compared with 54% of controls had no claims for comorbidities.
The impact of medical comorbidity in schizophrenia is significant because medical comorbidity affects quality of life and delivery of psychiatric and medical services. Dixon et al. reported that not only did persons with clinically diagnosed schizophrenia sampled from a variety of community and treatment settings have at least 1 medical problem, these persons also had worse perceived physical health status, more psychosis, more depression, and a greater likelihood of suicide attempt. Medical comorbidity can either cause or exacerbate the psychotic illness. 17 Because medical conditions may go unrecognized in this population, it is possible that unrecognized medical conditions contribute to prolonged hospitalizations and treatment failure. [17] [18] [19] [20] Primary care and behavioral health providers dealing with apparent exacerbations of mental illness in their patients with schizophrenia may need to consider whether symptoms are being driven by undiagnosed medical conditions. Unfortunately, failure to treat medical conditions in persons with schizophrenia is a common problem, 17-19'21 and these patients are more likely to report substantial barriers to care including economic barriers and delays in seeking care. m Even among insured persons with mental disorders, risks for delaying care or not receiving needed care are substantial. 22 Reasons include failure of psychiatric providers to ask about medical issues and patient inability to identify primary care provider by name. 2a Recognition of treatment barriers has ted to calls for integration of physical and mental health treatment services, 12.22,24-28 and integrated services have been successfully demonstrated in inpatient settings, outpatient clinics, detoxification units, and smoking cessation programs. 28-sl Furthermore, primary care providers may play an essential role in providing care to persons with schizophrenia, and may be first in line to assess medical conditions, especially in homeless shelters, walk-in clinics, or emergency treatment venues. Our results may guide the evaluation of persons with schizophrenia. For instance, the high rates of alcohol and polysubstance abuse increase the likelihood that presenting signs and symptoms of worsening psychosis may be related to substance intoxication, withdrawal, or medical conditions (e.g., hypothyroidism, congestive heart failure, diabetes). These findings also indicate that systems of care for primary and secondary prevention are important, especially for conditions related to smoking and infection.
Our study has several important strengths. Unlike studies conducted in a single hospital or clinic setting, our study analyzed a large population-based sample of adults. The data represent practice patterns of a diverse group of physicians in a wide geographical area. Because these subjects were commercially insured, the findings represent a population rarely studied, the commercially insured chronically mentally ill. We examined 6 years of claims data, with a follow-up period of approximately 40 months for subjects with schizophrenia. The use of rigorous case-finding methodology further ensures specificity of the schizophrenia-spectrum diagnoses and the generalizability of these finding to other men and women having schizophrenia. The use of the Klabunde comorbidity measure also ensures that the medical conditions are likely to be valid.
The limitations of this work should also be considered. First, this study included insured adults from Iowa, a racially homogeneous state. These results are generalizable to similarly insured populations but may not apply to racial and ethnic minorities and the uninsured. Second, limitations inherent to the analysis of claims data may have affected our results. Subjects who did not visit health care providers during the study period are not represented and could have only been captured if enrollment data were available. Thus, the "true" rates of comorbidity may be different from those reported. Physician failure to bill for services or failure to code medical diagnoses may have resulted in lower than expected rates of comorbidity. We have no reason to suspect that this differentially affected either the cases or controls. However, physician failure to provide needed medical assessments of persons with schizophrenia may have resulted in lower rates of claims for specifc medical diagnoses. Subjects with multiple insurers may also have resulted in lower than expected rates of service receipt represented in these data. Differences because of disparate length of follow-up were controlled for in the adjusted analyses, Yet, it is possible that persons with schizophrenia had longer follow-up times for fear of losing health benefits. 22 Finally, we had limited access to data regarding tobacco use, and risk for some conditions may be changed if tobacco use were entered into statistical models. However, logistic models controlling for smoking did not change the elevated risk for respiratory conditions in the Sokal et al. ~ t study.
In summary, this research contributes to the growing literature on medical and psychiatric comorbidity by describing a commercially insured population of men and women with schizophrenia compared with contemporaries without administrative claims for mental illness. Using rigorous methodology, we confirmed the findings of prior studies (e.g., increased comorbid diabetes) and extended these studies by identifying other comorbid medical conditions (e.g., hypothyroidism, anemia) in persons with schizophrenia. Our findings support the development and dissemination of coordinated medical and psychiatric systems of care. especially those directed at detection and the primary and secondary prevention of these medical conditions.
